4 transcripts
ITCI
Earnings call transcript
NASDAQ
2024 Q3
30 Oct 24
expenses to support the company's growth.
Our R&D expenses for Q3 were $66.8 million compared to $41.6 million for the same period in 2023. Our pipeline
ITCI
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
associated with our sales force expansion in the primary care segment in the second half of 2024.
We are also reducing our full year R&D expense guidance
ITCI
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
in our lumateperone R&D program. Accordingly, we have initiated our lumateperone pediatric program, which includes an open-label safety study
ITCI
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
through ongoing R&D efforts.
Today, I'm pleased to introduce our new program, ITI-1500. This program is focused on development of novel non
- Prev
- 1
- Next